Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT05 vs Simponi in rheumatoid arthritis
NCT05842213Phase 3Completed
- Sponsor
- Alvotech
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AVT05 in rheumatoid arthritis (RA) (2 arms), sponsored by Alvotech. Primary endpoint: Disease Activity Score 28-joint count using C-reactive protein at 16 weeks. Started Mar 2023; status: completed.
02
Drugs
AVT05
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05842213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842213.